非透析慢性肾脏病患者铁储备血清标志物与全因死亡及心血管事件风险相关
该研究纳入巴西、法国、美国和德国5145例非透析慢性肾脏病患者,以转铁蛋白饱和度(TSAT)和铁蛋白为暴露变量,采用Cox模型分析其与全因死亡和主要不良心血管事件(MACE)的关联。结果显示,与TSAT 26%-35%相比,TSAT≤15%的患者全因死亡和MACE风险最高;样条分析发现TSAT 40%时风险最低,TSAT≥46%时全因死亡风险升高。铁蛋白除≥300 ng/ml与全因死亡升高相关外,未见明确方向性关联。
要点
- TSAT≤15%与全因死亡和MACE风险最高相关。
- TSAT 40%时全因死亡和MACE风险最低。
- 铁蛋白≥300 ng/ml与全因死亡升高相关。
核心结论
- 以TSAT反映的铁缺乏与非透析慢性肾脏病患者全因死亡和MACE风险升高相关,无论是否合并贫血。
研究设计与样本
- 研究纳入来自巴西、法国、美国和德国的5145例非透析慢性肾脏病患者,数据来自CKD Outcomes and Practice Patterns Study。
- 暴露变量为首次可得的转铁蛋白饱和度(TSAT)和铁蛋白水平,采用Cox模型估计全因死亡和MACE的风险比(HR),并进行逐步校正。
- 采用线性样条模型进一步评估暴露-结局关联的功能形式。
主要发现
- 与TSAT 26%-35%的患者相比,TSAT≤15%的患者全因死亡和MACE的校正风险最高。
- 样条分析发现全因死亡和MACE风险最低点位于TSAT 40%。
- TSAT≥46%时全因死亡风险升高,但MACE风险未升高。
- 校正血红蛋白后效应估计相似。
- 铁蛋白除≥300 ng/ml与全因死亡升高相关外,未见明显方向性关联。
临床怎么用
- 在非透析慢性肾脏病患者中,应关注TSAT水平,TSAT≤15%提示铁缺乏并与不良结局风险升高相关。
- 铁蛋白≥300 ng/ml时需注意全因死亡风险升高,但铁蛋白与结局的关联不如TSAT明确。
- 需开展干预性研究评估补铁治疗及替代靶点治疗对临床结局的影响,以优化外源性铁剂使用策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 30%-45% of patients with nondialysis CKD have iron deficiency. Iron therapy in CKD has focused primarily on supporting erythropoiesis. In patients with or without anemia, there has not been a comprehensive approach to estimating the association between serum biomarkers of iron stores, and mortality and cardiovascular event risks. METHODS: The study included 5145 patients from Brazil, France, the United States, and Germany enrolled in the Chronic Kidney Disease Outcomes and Practice Patterns Study, with first available transferrin saturation (TSAT) and ferritin levels as exposure variables. We used Cox models to estimate hazard ratios (HRs) for all-cause mortality and major adverse cardiovascular events (MACE), with progressive adjustment for potentially confounding variables. We also used linear spline models to further evaluate functional forms of the exposure-outcome associations. RESULTS: Compared with patients with a TSAT of 26%-35%, those with a TSAT ≤15% had the highest adjusted risks for all-cause mortality and MACE. Spline analysis found the lowest risk at TSAT 40% for all-cause mortality and MACE. Risk of all-cause mortality, but not MACE, was also elevated at TSAT ≥46%. Effect estimates were similar after adjustment for hemoglobin. For ferritin, no directional associations were apparent, except for elevated all-cause mortality at ferritin ≥300 ng/ml. CONCLUSIONS: Iron deficiency, as captured by TSAT, is associated with higher risk of all-cause mortality and MACE in patients with nondialysis CKD, with or without anemia. Interventional studies evaluating the effect on clinical outcomes of iron supplementation and therapies for alternative targets are needed to better inform strategies for administering exogenous iron.
引用
- Guedes M, Muenz DG, Zee J, et al. Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. J Am Soc Nephrol. 2021. PMID: 34244326. doi:10.1681/ASN.2020101531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。